Publications by authors named "Arnold Yee"
Article Synopsis
- * The objective of the study was to assess the safety of the quadrivalent recombinant influenza vaccine (RIV4) compared to the quadrivalent standard-dose inactivated vaccine (SD-IIV4) among pregnant individuals and their infants.
- * Conducted by Kaiser Permanente Northern California, the observational study analyzed various pregnancy and birth outcomes, adjusting for factors like age and comorbidities, to determine the effects of RIV4 versus SD-IIV4 vaccinations during the 201
Article Synopsis
- Quadrivalent recombinant influenza vaccines contain higher doses of hemagglutinin protein and show less susceptibility to manufacturing errors compared to standard-dose egg-based vaccines, making it essential to assess their effectiveness in adults under 65.
- A cluster-randomized study was conducted with over 1.6 million participants across Kaiser Permanente Northern California facilities during the 2018-2019 and 2019-2020 flu seasons, comparing outcomes of high-dose recombinant vaccines versus standard-dose vaccines.
- Results indicated that the recombinant vaccine had a relative effectiveness of 15.3% over standard-dose vaccines in preventing confirmed influenza cases for adults aged 50 to 64, suggesting it may offer better protection.
Article Synopsis
- A multiyear study assessed the safety of the nine-valent human papillomavirus vaccine (HPV9, Gardasil®9) after its December 2014 licensure in the USA, comparing emergency department visits and hospitalizations soon after vaccination against control periods.
- The study included over 215,000 individuals, mostly aged 12-13, with findings showing a slight increase in certain health events, but most were attributable to other causes or preexisting conditions.
- No new safety concerns were identified, and all reported deaths during the study were unrelated to the HPV9 vaccine, confirming its overall safety profile.
Objectives: To evaluate a Kaiser Permanente Northern California physician training tool entitled "Effective Communication without Confrontation" aimed at improving communication with vaccine-hesitant parents, building trust, and alleviating physician stress surrounding vaccination visits.
Study Design: Trainings were held May to July 2015. Pre- and post-training surveys assessed physician comfort and perceived effectiveness in communicating with vaccine-hesitant parents.
Background: In 2010, the 13-valent pneumococcal conjugate vaccine (PCV13) replaced 7-valent PCV (PCV7) for protection against invasive pneumococcal disease (IPD). This study used laboratory surveillance data to examine the effect of PCV13 on IPD before and after PCV13 introduction among children aged 6 weeks to <6 years and those aged ≥6 weeks.
Methods: Observational laboratory-based IPD surveillance data were compared for the periods May 2010-April 2018 and May 2008-April 2010 (the PCV7 period) using a database of Kaiser Permanente Northern California (KPNC) members with laboratory-confirmed IPD.
In children <5 years, influenza is associated with higher risk of serious disease and hospitalization when compared with other age groups. Influenza vaccination reduces the risk of influenza and vaccination may attenuate the severity of disease. Recent studies in Europe suggest that classifying influenza disease as mild versus moderate-to-severe (M-S) using a novel definition may be clinically significant.
View Article and Find Full Text PDFIt is unclear whether HIV-infected individuals remain at higher risk of invasive pneumococcal disease (IPD) compared with HIV-uninfected individuals. We conducted a cohort study of HIV-infected and demographically matched HIV-uninfected adults within Kaiser Permanente Northern California during the period 1996-2011. We used Poisson models to obtain rate ratios (RRs) for incident IPD associated with HIV infection and other risk factors.
View Article and Find Full Text PDFPurpose: In the United States, the 13-valent pneumococcal conjugate vaccine is recommended in persons ⩾65years of age, and persons ⩽65years of age with immunocompromising (IC) conditions. For invasive pneumococcal disease (IPD) prevention in those ⩽65 with non-IC medical conditions, the 23-valent polysaccharide vaccine is recommended. This group is at higher risk of IPD than the general population, but the level of risk is not well-quantified.
View Article and Find Full Text PDF